



Scottish
Lipid
Forum



SCOTTISH LIPID FORUM & SHARP HYBRID MEETING 2021

SHARP PRIZE ABSTRACTS

18TH NOVEMBER 2021

ROYAL COLLEGE OF PHYSICIANS OF EDINBURGH

Title: Cumulative atherosclerotic burden in patients with angina and non-obstructive coronary artery disease (ANOCA).

Authors: Daniel Ang¹, Jaclyn Carberry¹, Colin Berry¹.

¹British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.

Abstract:

Background: Increased atherosclerotic burden is associated with worse prognosis. Up to 50% of patients with angina have non-obstructive coronary artery disease (ANOCA), amongst whom microvascular angina (MVA) is present in approximately half. Despite recent guideline recommendations, prescription of cardiovascular secondary prevention medication for this population varies widely among clinicians.

Aims: To determine the epicardial atherosclerotic burden in patients with ANOCA, specifically those with microvascular angina.

Methods: $n=53$ consecutive patients with ANOCA undergoing thermodilution microvascular function testing were included. Cardiovascular risk factors and clinical history were documented. MVA was diagnosed if coronary function tests were abnormal. Cumulative atherosclerotic burden (Gensini scoring) was assessed per patient and compared between groups.

Results: Of $n=53$ patients, $n=20$ (median age=62 years, 45% Male) had MVA based on abnormal coronary function tests. Co-morbidities include 60% smoking history, 50% hypertension and 10% diabetes mellitus. The median LVEDP=8mmHg. The mean Gensini score was 8.5 in patients with MVA versus 6.0 in those with normal coronary function tests, $p=0.05$.

Conclusion: MVA is associated with a higher epicardial cumulative atherosclerotic burden, which might explain its association with major adverse cardiovascular events. These results support the prescription of secondary prevention medication, in particular statins.

(193 words)